Mabwell to Showcase Six Novel Cancer Therapeutics at 2025 AACR Annual Meeting
核心洞察
Mabwell (搜索) will present six preclinical studies at the 2025 AACR Annual Meeting in Chicago, highlighting their expanding oncology pipeline with innovative antibody-drug conjugates and T-cell engagers.
The company's presentations include promising data on novel therapeutics targeting B7-H3 (搜索), CLDN1 (搜索), and cadherin 17 (搜索) for solid tumors, as well as a LILRB4xCD3 bispecific T-cell engager for acute myeloid leukemia (搜索).
Mabwell (搜索)'s research demonstrates significant advances in cancer treatment approaches, including synergistic effects between their B7-H3 (搜索)-targeting ADC and PARP inhibitors (搜索), and a new T-cell engager platform optimized for both hematologic and solid tumors.
Mabwell (搜索) (688062.SH), an innovation-driven biopharmaceutical company, has announced plans to present results from six preclinical studies at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The conference, one of the world's largest cancer research gatherings, will be held in Chicago from April 25-30, 2025.
The company's presentations will showcase their expanding oncology pipeline, featuring novel antibody-drug conjugates (ADCs) and bispecific T-cell engagers designed to address various cancer types with significant unmet needs.
Novel ADCs Show Promise Against Multiple Cancer Types
Among Mabwell (搜索)'s most notable presentations is a study demonstrating that their B7-H3 (搜索)-targeting antibody-drug conjugate, 7MW3711, synergistically enhances antitumor activity when combined with PARP inhibitors (搜索) in B7-H3-positive cancers. This finding suggests potential for combination therapy approaches that could improve outcomes for patients with tumors expressing the B7-H3 protein.
The company will also present data on MW-C01/C02 (搜索), novel claudin 1 (CLDN1 (搜索))-targeting ADCs that have demonstrated "compelling anti-tumor efficacy and favorable safety profiles" in preclinical studies. CLDN1 is a tight junction protein that has emerged as a promising target for cancer therapy due to its overexpression in various tumor types.
For gastrointestinal cancers (搜索) specifically, Mabwell (搜索) will showcase 7MW4911 (搜索), a novel cadherin 17 (搜索)-targeting ADC. According to the abstract, this therapeutic has demonstrated "potent efficacy in preclinical models of gastrointestinal cancers," potentially addressing a significant area of unmet need in oncology.
Innovative T-Cell Engagers for Hematologic and Solid Tumors
Beyond ADCs, Mabwell (搜索) is advancing novel T-cell engager platforms. The company will present 2MW7061 (搜索), a LILRB4xCD3 bispecific T-cell engager specifically targeting monocytic acute myeloid leukemia (搜索) (AML). LILRB4 (搜索) has been identified as a potential therapeutic target in AML, particularly in monocytic subtypes of the disease.
Additionally, Mabwell (搜索) will showcase an innovative T-cell engager platform with optimized CD3 (搜索) affinity and formats designed for both hematologic and solid tumors. This platform technology could potentially serve as the foundation for multiple future therapeutics targeting different cancer types.
Advancing ADC Technology
The company is also making strides in ADC technology development. Researchers will present on the design and synthesis of a novel camptothecin analog called MF6, specifically developed for application in site-specific antibody-drug conjugates. This represents an important advancement in payload technology for ADCs, potentially improving efficacy and safety profiles of future therapeutics.
Mabwell's Growing Oncology Pipeline
These presentations highlight Mabwell (搜索)'s expanding presence in oncology drug development. The company currently has 16 pipeline products in various stages of development, including 12 novel drug candidates and 4 biosimilars, focusing on therapeutic areas including oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases.
"Our presentations at AACR demonstrate our commitment to developing innovative cancer therapeutics that address significant unmet medical needs," said a Mabwell (搜索) representative in a statement. "We're particularly encouraged by the preclinical data for our ADCs and T-cell engagers, which show promising efficacy and safety profiles."
Manufacturing Capabilities Support Clinical Translation
To support the clinical translation of these preclinical candidates, Mabwell (搜索) has established robust manufacturing capabilities. The company's Taizhou factory complies with international GMP standards regulated by the NMPA, FDA, and EMA, and has passed EU QP Audit. Additional large-scale manufacturing facilities in Shanghai and an ADC commercialization manufacturing base in Taizhou are currently under construction.
The AACR Annual Meeting serves as a premier forum for researchers, clinicians, and industry representatives to share the latest advances in cancer research. Mabwell (搜索)'s participation with six presentations underscores the company's growing contribution to innovative cancer therapeutics development.
For oncologists and researchers interested in these novel therapeutics, the poster presentations will be available at the AACR Annual Meeting according to the following schedule:
- B7-H3-targeting ADC (7MW3711): April 27, 2025, 2:00-5:00 PM
- Novel camptothecin analog MF6: April 29, 2025, 2:00-5:00 PM
- CLDN1-targeting ADCs (MW-C01/C02): April 28, 2025, 9:00 AM-12:00 PM
- LILRB4xCD3 bispecific T-cell engager (2MW7061): April 28, 2025, 9:00 AM-12:00 PM
- T-cell engager platform: April 28, 2025, 2:00-5:00 PM
- Cadherin 17-targeting ADC (7MW4911): April 29, 2025, 2:00-5:00 PM